Low-fluence photodynamic therapy in chronic central serous chorioretinopathy

Abstract

ObjectiveTo evaluate safety and efficacy of low-fluence photodynamic therapy (LFPDT) with verteporfin in patients affected with chronic central serous chorioretinopathy (CCSC), in terms of visual acuity (VA) and macular morphology measured with optical coherence tomography (OCT). MethodsA retrospective, non-randomized and interventionist analysis was performed on 16 eyes in 15 patients with CCSC treated with LFPDT. Best corrected visual acuity (BCVA) with ETDRS optotypes and central foveal thickness (CFT) in OCT were evaluated as outcome measures. ResultsThe mean follow-up was 10.8 months. The mean BCVA improved from 58.12 to 68.68 ETDRS letters, and CFT decreased from 280.5 to 172.18μm, with subretinal fluid resolution in 14 eyes (87.5%), two of them after a second LFTPD. No complications related to treatment were recorded. ConclusionsLFPDT with verteporfin can be useful in CCSC to stabilize or improve BCVA, reabsorb subretinal fluid and reduce CFT. Randomized studies with a longer follow-up are required to assure the role of this treatment and to optimize parameters for higher efficacy and safety in CCSC patients.